瑞舒伐他汀钙片治疗原发性高胆固醇血症的临床研究

发布时间：2018-09-18 13:59

【摘要】：目的观察瑞舒伐他汀钙片对原发性高胆固醇血症患者的临床疗效及其对患者血清超敏C反应蛋白(hs-CRP)、可溶性血管细胞黏附因子~(-1)(s VCAM~(-1))的影响。方法将86例原发性高胆固醇血症患者分为试验组与对照组,每组43例。对照组患者给予阿托伐他汀钙片10 mg·d~(-1),口服;试验组患者给予瑞舒伐他汀钙片10 mg·d~(-1),口服。2组患者均治疗8周。比较2组患者的临床疗效、血脂水平及血清hs-CRP、s VCAM~(-1)水平。结果治疗后,试验组总有效率为95.35%(41/43例),对照组为79.07%(34/43例,P0.05)。治疗后,试验组血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)分别为(4.38±0.89),(1.54±0.79),(2.23±0.82)mmol·L~(-1),对照组分别为(4.79±0.87),(1.90±0.83),(2.61±0.89)mmol·L~(-1),差异有统计学意义(P0.05)。治疗后,试验组和对照组hs-CRP分别为(4.83±1.13),(5.12±1.78)mg·L~(-1),s VCAM~(-1)分别为(0.37±0.15),(0.39±0.13)mg·L~(-1),差异有统计学意义(P0.05)。2组患者主要的药物不良反应为便秘、腹痛、恶心,试验组和对照组药物不良反应发生率分别为11.63%(5/43例),13.95%(6/43例),差异无统计学意义(P0.05)。结论瑞舒伐他汀钙片治疗原发性高胆固醇血症有较好的临床疗效和安全性。
[Abstract]:Objective to observe the clinical effect of rosuvastatin calcium tablets on serum hypersensitive C-reactive protein (hs-CRP) and soluble vascular cell adhesion factor-1 () (s VCAM~ (-1) in patients with primary hypercholesterolemia. Methods 86 patients with primary hypercholesterolemia were divided into experimental group and control group with 43 cases in each group. The patients in the control group were given the calcium tablet of Atto vastatin for 10 mg d ~ (-1), the patients in the test group were given the calcium tablet of rosuvastatin for 10 mg d ~ (-1), and the patients in the oral group were treated for 8 weeks. The clinical efficacy, blood lipid level and serum hs-CRP,s VCAM~ (-1) level were compared between the two groups. Results after treatment, the total effective rate of the trial group was 95.35% (41 / 43 cases) and that of the control group was 79.07% (34 / 43 cases P 0.05). After treatment, serum total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) was (4.38 卤0.89), (1.54 卤0.79), (2.23 卤0.82) mmol L-1 in the experimental group and (4.79 卤0.87), (1.90 卤0.83), (2.61 卤0.89) mmol L-1 in the control group (P0.05). After treatment, the hs-CRP of experimental group and control group were (4.83 卤1.13), (5.12 卤1.78) mg L ~ (-1) VCAM~ (0.37 卤0.15), (, 0.39 卤0.13) mg L ~ (-1), respectively. The main adverse drug reactions were constipation, abdominal pain and nausea in group (P0.05). The incidence of adverse drug reactions in the trial group and the control group was 11.63% (5 / 43 cases) and 13.95% (6 / 43 cases) respectively. The difference was not statistically significant (P0.05). Conclusion Risuvastatin calcium tablets have good clinical efficacy and safety in the treatment of primary hypercholesterolemia.
【作者单位】：北京京煤集团总医院内分泌科;
【分类号】：R589.2

【参考文献】